Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 5/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | F9 | P00740 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 2/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.33 |
| ▸ | DUSP4 | Q13115 | 1/20 | 0.33 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.31 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2461637 | 0.91 | MEN1 (0.38) | NR1H2IGF1RMEN1KMT2A | |
| SCHEMBL2460721 | 0.89 | PTGER1 (0.35) | NR1H2NR1H3 | |
| SCHEMBL2460739 | 0.89 | EGFR (0.38) | F9IGF1RLMNAMEN1KMT2A | |
| SCHEMBL2460704 | 0.89 | PARP10 (0.31) | — | |
| SCHEMBL2460315 | 0.89 | NPC1 (0.38) | NR1H2NR1H3NPC1RAB9ALMNA | |
| SCHEMBL2463513 | 0.88 | MEN1 (0.46) | RAB9AIGF1RLMNAPOLBMEN1 | |
| SCHEMBL2460200 | 0.87 | MAOB (0.37) | NR1H2NR4A2F9IGF1RMAOB | |
| SCHEMBL2459795 | 0.87 | GRIN1 (0.33) | MAOB | |
| SCHEMBL2462400 | 0.87 | IGF1R (0.35) | NR1H2F9IGF1RMEN1KMT2A | |
| SCHEMBL2460218 | 0.86 | NR4A2 (0.38) | NR4A2F9IGF1REGLN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675860-B1 | IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS | OSI PHARM INC (US) | 2011-09-21 | — | — | EP | claimed |
| US-7459554-B2 | Imidazopyrazine tyrosine kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | claimed |
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | BECK PATRICIA A | 2008-09-18 | — | — | US | claimed |
| JP-2007509060-A | — | — | 2007-04-12 | — | — | JP | claimed |
| EP-1675860-A2 | IMIDAZO[1,5-A]PYRAZINE TYROSINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-07-05 | — | — | EP | claimed |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-04-20 | — | — | US | claimed |
| WO-2005037836-A2 | IMIDAZO ‘1, 5 - A ! PYRAZINE TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1675860-B1 | IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS | OSI PHARM INC (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-7459554-B2 | Imidazopyrazine tyrosine kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | BECK PATRICIA A | 2008-09-18 | — | — | US | disclosed |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227788-A9 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS | IGF1R, IRS1, IGFBP1 | NR1H2 2603/4885NR1H3 3680/4885NPC1 4262/4885 |
| US-20060084654-A1 | Imidazopyrazine tyrosine kinase inhibitors | IGF1R, IRS1, IGFBP1 | NR1H2 2603/4885NR1H3 3680/4885NPC1 4262/4885 |
| US-20090181940-A1 | Imidazopyrazine Tyrosine Kinase Inhibitors | IGF1R, IRS1, IGFBP1 | NR1H2 2603/4885NR1H3 3680/4885NPC1 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.